Company news

Moleculin Biotech, Inc. (NASDAQ:MBRX) news

Moleculin Biotech, Inc. news releases on 6ix. Latest, Aug 19, 2022: Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a…

Moleculin Biotech, Inc. (NASDAQ:MBRX) news

Press releases — page 4

Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update

Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

Moleculin Announces Corporate Rebranding and Launch of New Website

Moleculin Reports Full Year Financial Results and Provides Programs Update

Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Moleculin Announces Inclusion in the Russell 2000® Index

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

Moleculin Announces Full Exercise of Over-Allotment Option

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

Moleculin Announces Proposed Underwritten Public Offering

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066

Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020

Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19

Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors

Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

Moleculin Appoints Elizabeth Cermak to Board of Directors

Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University

Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites

Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122